Detect Lab history

It was not until 1907 when Landsteiner elucidated the previously unknown mechanism behind the Wassermann reaction via identification of lipoid “autotoxic” substances, with which Wassermann antibodies form immune complexes in the presence of lecithin and cholesterol.

After he became Director in 1924, Hoover encouraged the Bureau to keep an eye on the latest insights into Bureau work that science provided.

By 1930, the Bureau began using outside experts hired for such work on a case-by-case basis.

5The official date set by E. P. Coffey, the Assistant Director in charge of Division 5. [Note by E. P. C. on Memo, Appel to Director, 11/26/1932, 80-11-86]. Existing records indicate that the lab was in operation as early as September of that year.

During the summer of 1933, he began compiling frequency tables for use in cases involving ciphers and pursued research into marking bills for ransom drops.

At its peak in 1945, the Rad Lab employed 3500 people and was spending close to $4 million a month.

The fluorescent antibody test for syphilis was first reported in 1957 by Deacon, Falcone, and Harris.

The Treponema pallidum Hemagglutination Assay (TPHA) was introduced in 1966 by Takayuki Tomizawa and Shigeo Kasamatsu, who developed the test with a goal to simplify the process of treponemal antibody testing.

1974 National Health Laboratories (NHL) is formed Revlon, Inc. enters the lab business and, after a number of acquisitions, adopts the name National Health Laboratories Incorporated (NHL).

Using these fabrication techniques, the first real lab-on-a-chip was created in 1979 at Stanford University for gas chromatography.

1982 Acquisition of Biomedical Reference Laboratories After a number of acquisitions, Hoffmann-La Roche acquires Biomedical Reference Laboratories.

1983 Merger forms Roche Biomedical Laboratories (RBL) Hoffmann-La Roche merges all of its laboratory companies into one company, now called Roche Biomedical Laboratories (RBL).

1994 National Health Laboratories grows NHL further broadens its laboratory testing capabilities by acquiring the sixth-largest clinical lab in the United States, Allied Clinical Health.

1995 LabCorp is created NHL and RBL merge to become one of the largest clinical lab providers in the world.

2000 National Genetics Institute LabCorp acquires Los Angeles-based National Genetics Institute, allowing LabCorp to gain NGI’s ultra-sensitive hepatitis C testing capability.

2001 ViroMed acquisition ViroMed, one of the leading laboratories in molecular microbial testing using real-time PCR platforms, becomes a part of LabCorp.

2002 LabCorp acquires Dynacare With the acquisition of Dynacare, LabCorp expands its geographic presence in the western and midwestern United States, as well as creating LabCorp’s first significant international presence in Canada.

2003 DIANON Systems becomes part of LabCorp LabCorp continues to build the most robust anatomic pathology capabilities in the world by acquiring DIANON Systems, now Dianon Pathology.

2005 LabCorp acquires Esoterix, Inc. and US LABS Both Esoterix, Inc. and US LABS become part of the LabCorp family.

2006 Litholink becomes part of LabCorp LabCorp acquires Litholink, a leading provider of testing that provides targeted treatment information, helping physicians better manage and prevent chronic diseases, including kidney stones and chronic kidney disease.

2008 Tandem Laboratories purchased by LabCorp LabCorp expands its clinical trials, personalized medicine, and companion diagnostic capabilities by purchasing Tandem Laboratories.

2009 Monogram Biosciences is purchased by LabCorp LabCorp purchases Monogram Biosciences, a recognized leader in the discovery and commercialization of products to guide and improve the treatment of HIV, cancer, and other serious diseases.

2010 LabCorp finalizes acquisition of Genzyme Genetics LabCorp completes its $1 billion acquisition of Genzyme Genetics, a business unit of Genzyme Corporation.

2011 Orchid Cellmark, Inc. becomes part of LabCorp LabCorp acquires Orchid Cellmark, Inc. (Orchid), harmonizing two experienced and highly qualified forensics and family relationship laboratories.

2014 Sep 7;14(17):3159-64. doi: 10.1039/c4lc00142g., Smartphone technology can be transformative to the deployment of lab-on-chip diagnostics., Erickson D, O’Dell D, Jiang L, Oncescu V, Gumus A, Lee S, Mancuso M, Mehta S.

Jie Hu, Xingye Cui, Yan Gong, Xiayu Xu, Bin Gao, Ting Wen, Tian Jian Lu, Feng Xu, “Portable microfluidic and smartphone-based devices for monitoring of cardiovascular diseases at the point of care”, Biotechnology Advances, 34, 3, 2016, 305-320, doi: 10.1016/j.biotechadv.2016.02.008

Materials for microfluidic chips fabrication : a review 2017 Microfluidics involve different types of devices, and materials for microfluidic fabrication must be selected while bearing in mind all the requirements necessary for building a fine microfluidic device.

A study in 2018 using a rabbit infection model demonstrated that T. pallidum itself contained a cardiolipin antigen but with weak immunogenicity, while active T. pallidum induced higher non-treponemal antibody production in the host.

2019 LabCorp acquires MNG Laboratories On March 1, 2019, LabCorp acquires MNG Laboratories, an internationally recognized clinical diagnostic leader that specializes in next generation sequencing (NGS) and complex biochemical testing for neurology.